• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma.

作者信息

Song Yu-Qin, Zhang Hui-Lai, Huang Hui-Qiang, Zhang Qing-Yuan, Jing Hong-Mei, Wang Chao, Wu Chun, Li Dong-Hang, Dai Yu, Humphrey Kathryn, Zhu Jun

机构信息

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing.

Tianjin Medical University Cancer Institute and Hospital, Tianjin.

出版信息

Haematologica. 2024 Apr 1;109(4):1269-1273. doi: 10.3324/haematol.2023.283802.

DOI:10.3324/haematol.2023.283802
PMID:37855035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10985436/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a752/10985436/da8e6e432974/1091269.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a752/10985436/da8e6e432974/1091269.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a752/10985436/da8e6e432974/1091269.fig1.jpg

相似文献

1
Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma.在接受过大量治疗的复发或难治性弥漫性大B细胞淋巴瘤中国患者中， glofitamab单药治疗诱导了高完全缓解率且安全性可控。
Haematologica. 2024 Apr 1;109(4):1269-1273. doi: 10.3324/haematol.2023.283802.
2
Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.双重靶点困境：复发性难治性弥漫性大B细胞淋巴瘤中依泊妥单抗与戈利妥单抗的抉择
Expert Rev Hematol. 2023 Jul-Dec;16(12):915-918. doi: 10.1080/17474086.2023.2285978. Epub 2023 Dec 18.
3
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.戈利木单抗，一种新型、双价 CD20 靶向 T 细胞衔接双特异性抗体，在复发或难治性 B 细胞淋巴瘤中诱导持久完全缓解：一项 I 期试验。
J Clin Oncol. 2021 Jun 20;39(18):1959-1970. doi: 10.1200/JCO.20.03175. Epub 2021 Mar 19.
4
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.奥德罗内昔单抗，一种针对 CD20 阳性 B 细胞恶性肿瘤的人源 CD20×CD3 双特异性抗体（ELM-1）：在一项单臂、多中心、1 期临床试验中，复发或难治性非霍奇金淋巴瘤队列的结果。
Lancet Haematol. 2022 May;9(5):e327-e339. doi: 10.1016/S2352-3026(22)00072-2. Epub 2022 Apr 1.
5
An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas.评估 glofitamab，首个用于治疗复发或难治性大 B 细胞淋巴瘤的固定疗程双特异性抗体。
Expert Opin Biol Ther. 2024 Jan-Feb;24(1-2):7-13. doi: 10.1080/14712598.2024.2312243. Epub 2024 Feb 2.
6
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.戈利木单抗治疗复发/难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2022 Dec 15;387(24):2220-2231. doi: 10.1056/NEJMoa2206913. Epub 2022 Dec 11.
7
Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma.试验观察：双特异性抗体治疗复发或难治性大 B 细胞淋巴瘤。
Oncoimmunology. 2024 Mar 3;13(1):2321648. doi: 10.1080/2162402X.2024.2321648. eCollection 2024.
8
Glofitamab: First Approval.格罗菲妥单抗：美国首次批准
Drugs. 2023 Jul;83(10):935-941. doi: 10.1007/s40265-023-01894-5.
9
Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.双特异性抗体作为单药或联合治疗血液系统恶性肿瘤：EHA 2023 年年会的最新更新。
Expert Opin Biol Ther. 2023 Jul-Dec;23(12):1193-1195. doi: 10.1080/14712598.2023.2273276. Epub 2023 Dec 28.
10
Update on bi-specific monoclonal antibodies for blood cancers.血液癌症的双特异性单克隆抗体的最新进展。
Curr Opin Oncol. 2023 Sep 1;35(5):441-445. doi: 10.1097/CCO.0000000000000966. Epub 2023 Jul 5.

引用本文的文献

1
Glofitamab treatment of Richter transformation with isolated central nervous system involvement: a case report.戈利妥单抗治疗孤立性中枢神经系统受累的Richter转化：一例报告
Front Immunol. 2025 Jul 18;16:1635589. doi: 10.3389/fimmu.2025.1635589. eCollection 2025.
2
Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?单克隆抗体的单药治疗及联合疗法：滤泡性淋巴瘤的情况如何？
Cancers (Basel). 2025 May 8;17(10):1602. doi: 10.3390/cancers17101602.
3
Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report.

本文引用的文献

1
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.戈利木单抗治疗复发/难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2022 Dec 15;387(24):2220-2231. doi: 10.1056/NEJMoa2206913. Epub 2022 Dec 11.
2
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma.大 B 细胞淋巴瘤中 CD19-CAR-T 治疗失败后的首次治疗结果。
Leukemia. 2023 Jan;37(1):154-163. doi: 10.1038/s41375-022-01739-2. Epub 2022 Nov 5.
3
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
使用戈利妥单抗成功治疗由滤泡性淋巴瘤转化而来的原发性难治性弥漫性大B细胞淋巴瘤/高级别B细胞淋巴瘤-MYC/BCL2：一例报告
Front Immunol. 2025 Mar 31;16:1566035. doi: 10.3389/fimmu.2025.1566035. eCollection 2025.
4
Bispecific Antibodies for Lymphoid Malignancy Treatment.用于治疗淋巴系统恶性肿瘤的双特异性抗体。
Cancers (Basel). 2024 Dec 31;17(1):94. doi: 10.3390/cancers17010094.
5
Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial.Loncastuximab tesirine治疗中国复发或难治性弥漫性大B细胞淋巴瘤患者：一项多中心、开放标签、单臂II期试验。
Haematologica. 2025 Mar 1;110(3):683-692. doi: 10.3324/haematol.2024.284973.
6
Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis.接受双特异性抗体治疗的淋巴瘤患者的感染：一项系统评价和荟萃分析。
Blood Adv. 2024 Jul 9;8(13):3555-3559. doi: 10.1182/bloodadvances.2024012916.
7
Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma.试验观察：双特异性抗体治疗复发或难治性大 B 细胞淋巴瘤。
Oncoimmunology. 2024 Mar 3;13(1):2321648. doi: 10.1080/2162402X.2024.2321648. eCollection 2024.
戈利木单抗，一种新型、双价 CD20 靶向 T 细胞衔接双特异性抗体，在复发或难治性 B 细胞淋巴瘤中诱导持久完全缓解：一项 I 期试验。
J Clin Oncol. 2021 Jun 20;39(18):1959-1970. doi: 10.1200/JCO.20.03175. Epub 2021 Mar 19.
4
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.CD20-TCB 联合奥滨尤妥珠单抗预处理用于血液系统恶性肿瘤的下一代治疗。
Clin Cancer Res. 2018 Oct 1;24(19):4785-4797. doi: 10.1158/1078-0432.CCR-18-0455. Epub 2018 May 1.
5
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.难治性弥漫性大B细胞淋巴瘤的预后：国际SCHOLAR-1研究结果
Blood. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3.
6
Toxicities of chimeric antigen receptor T cells: recognition and management.嵌合抗原受体T细胞的毒性：识别与管理
Blood. 2016 Jun 30;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20.
7
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.霍奇金淋巴瘤和非霍奇金淋巴瘤初始评估、分期及反应评估的建议：卢加诺分类
J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800.
8
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.利妥昔单抗时代复发的大 B 细胞淋巴瘤的自体移植挽救治疗方案。
J Clin Oncol. 2010 Sep 20;28(27):4184-90. doi: 10.1200/JCO.2010.28.1618. Epub 2010 Jul 26.